Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Geisler, M. Dowsett, P. Lønning (2002)
Letrozole is more effective than anastrozole in suppressing total body aromatization and plasma strogen levels in postmenopausal breast cancer patients
J. Geisler, N. King, G. Anker, G. Ornati, E. Salle, P. Lønning, M. Dowsett (1998)
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 9
Alexandra Resch, Eva Biber, Michael Seifert, Heinrich Resch (1998)
Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer.Acta oncologica, 37 7-8
N. Kirma, K. Gill, U. Mandava, R. Tekmal (2001)
Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice.Cancer research, 61 5
M. Thangaraju, K. Kumar, Rengasamy Gandhirajan, P. Sachdanandam (1994)
Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancerCancer, 73
J. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, M. Voneuler (2000)
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 22
J. Bonneterre, A. Buzdar, J.M. Nabholtz (2001)
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer, 92
H. Mouridsen, M. Gershanovich, Yan Sun, R. Pérez-Carrión, C. Boni, A. Monnier, J. Apffelstaedt, Robert Smith, H. Sleeboom, F. Jänicke, A. Płużańska, M. Dank, D. Becquart, P. Bapsy, E. Salminen, R. Snyder, M. Lassus, J. Verbeek, Beatrix Staffler, H. Chaudri-Ross, M. Dugan (2001)
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 10
AL Jones, T. Powles, JG Treleaven, JF Burman, MC Nicolson, H-I Chung, S. Ashley (1992)
Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.British Journal of Cancer, 66
S. Glück (2001)
Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined AnalysisCancer, 92
E. Calle, H. Miracle-McMahill, M. Thun, C. Heath (1995)
Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women.Journal of the National Cancer Institute, 87 7
J. Wojtacki, W. Kruszewski, M. Sliwinska (2000)
Effect of non-steroidal aromatase inhibitors (AI) on serum lipid profile in patients with breast cancer: preliminary report [abstract 146]Eur J Cancer, 36
A. Brodie, D. Jelovac, B. Long (2003)
Treatment Strategies Using Letrozole and Tamoxifen in a Xenograft Model for Breast CancerAmerican Journal of Cancer, 2
D. Ross, M. Whitehead (1995)
Hormonal manipulation and gynaecological cancer: the tamoxifen dilemma.Current opinion in obstetrics & gynecology, 7 1
M. Baum, A. Budzar, J. Cuzick, J. Forbes, J. Houghton, J. Klijn, T. Sahmoud (2002)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 359
J. Geisler, B. Haynes, G. Anker, M. Dowsett, P. Lønning (2002)
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 3
R. Paridaens, L. Dirix, L. Beex, M. Nooij, T. Čufer, C. Lohrisch, L. Biganzoli, I. Hoorebeeck, L. Duchateau, J. Lobelle, M. Piccart (2000)
Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial, 19
Angela Brodie, W. Schwarzel, A. Shaikh, H. Brodie (1977)
The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.Endocrinology, 100 6
M. Baum (2002)
Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group)
L. Bergman, M. Beelen, M. Gallee, H. Hollema, Jantien Benraadt, F. Leeuwen (2000)
Risk and prognosis of endometrial cancer after tamoxifen for breast cancerThe Lancet, 356
N. Wolmark, B. Dunn (2001)
The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P1)Ann N Y Acad Sci, 949
M. Clarke, R. Collins, C. Davies, J. Godwin, R. Gray, R. Peto (1998)
Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 352
L. Dirix, M.J. Piccant, G. Lohrisch (2001)
Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn [abstract 114]Proc Am Soc Clin Oncol, 20
A.H. Brodie, D. Jelovac, B. Long (2003)
Treatment strategies using letrozole and tamoxifen in a xenograft model for breast cancer: combined treatment versus alternating or sequential treatmentAm J Cancer, 2
H. Mouridsen, M. Gershanovich, Yan Sun, R. Pérez-Carrión, C. Boni, A. Monnier, J. Apffelstaedt, Robert Smith, H. Sleeboom, F. Jaenicke, A. Płużańska, M. Dank, D. Becquart, P. Bapsy, E. Salminen, R. Snyder, H. Chaudri-Ross, R. Lang, P. Wyld, A. Bhatnagar (2003)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 11
L. Bergman, M.L. Beelen, M.P. Gallee (2000)
Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group: assessment of liver and endometrial cancer risk following tamoxifenLancet, 356
(1998)
Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 351
J. Bonneterre, B. Thürlimann, J. Robertson, M. Krzakowski, L. Mauriac, P. Koralewski, I. Vergote, A. Webster, M. Steinberg, M. Euler (2000)
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 22
S. Masamura, S. Santner, Daniel Heitjan, R. Santen (1995)
Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells.The Journal of clinical endocrinology and metabolism, 80 10
H. Heshmati, S. Khosla, S. Robins, W. O'Fallon, L. Melton, B. Riggs (2002)
Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal WomenJournal of Bone and Mineral Research, 17
N. Wolmark, B. Dunn (2001)
The Role of Tamoxifen in Breast Cancer PreventionAnnals of the New York Academy of Sciences, 949
M. Elisaf, E. Bairaktari, C. Nicolaides, B. Kakaidi, C. Tzallas, A. Katsaraki, N. Pavlidis (2001)
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.European journal of cancer, 37 12
M. Dowsett, A. Jones, S. Johnston, S. Jacobs, P. Trunet, I. Smith (1995)
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 1 12
P. Lønning (1996)
Pharmacology of new aromatase inhibitorsThe Breast, 5
Third-generation aromatase inhibitors (AIs) have shown at least equivalent or superior efficacy to tamoxifen in the first-line treatment of women with hormone-dependent metastatic breast cancer. Similar results have been obtained in the neoadjuvant setting. These studies suggested that AIs may also have significant efficacy in the adjuvant setting, and evaluation against tamoxifen is ongoing.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.